Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as lenalidomide alongside standard fludarabine therapy. At the Paris symposium John Gribben gave Peter Goodwin the latest details.
Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of
Post a comment